Verve Therapeutics, Inc. (VERV)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research
View more

Current Price

as of Jun 18, 2025

$11.12

P/E Ratio

N/A

Market Cap

$991.27M

Description
Add to research
View more

Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.

Metrics
Add to research
View more

Overview

  • HQBoston, MA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerVERV
  • Price$11.12-2.28%

Trading Information

  • Market cap$991.27M
  • Float73.77%
  • Average Daily Volume (1m)7,846,345
  • Average Daily Volume (3m)5,181,062
  • EPS-$2.11

Company

  • Revenue$59.61M
  • Rev growth (1yr)479.03%
  • Net income-$31.03M
  • Gross margin94.80%
  • EBITDA margin-105.90%
  • EBITDA-$34.92M
  • EV-$22.64M
  • EV/Revenue-0.38
  • P/EN/A
  • P/S16.56
  • P/B2.09
  • Debt/Equity14.50
Documents
Add to research
View more